TD Cowen analyst Charles Rhyee upgraded Veeva (VEEV) to Buy from Hold with a price target of $380, up from $297. The company is well positioned to post sales growth above consensus estimates due to multiple drivers, including the secular shift to large pharma insourcing and the Iqvia (IQV) partnership, the analyst tells investors in a research note. TD expects Veeva shares to re-rate moving forward.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VEEV:
- Veeva Systems: Strong Market Position and Growth Potential Justify Buy Rating
- Bristol Myers commitment a reminder of Veeva’s progress, says Stifel
- Veeva says Bristol Myers commits to Veeva Vault CRM
- Aquestive, Veeva, Oklo, BioMarin, TKO: Trending by Analysts
- Veeva Systems: Strategic Positioning and Growth Potential Justify Buy Rating